Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inhibikase Therapeutics announced the issuance of non-qualified stock options totaling 685,718 shares to five newly hired non-executive employees as part of its 2026 Inducement Equity Plan. The options are priced at $1.68 per share, matching the closing stock price on the grant date, with a 10-year term and a vesting schedule extending over four ye…